Boltz PBC has partnered with Excelra to use data from Excelra’s GOSTAR database in training ADMET models for its BoltzMol-1 drug-discovery system. The models estimate how compounds behave in the body and are intended to help filter out poor candidates before researchers buy or synthesize them.
Boltz says the GOSTAR-trained models matched or beat a leading open-source ADMET package on unfamiliar chemistry, with the biggest gains in solubility and permeability. The companies did not name the package or provide numerical scores in the announcement.
Why it matters
Drug researchers may be able to screen out some unsuitable compounds earlier, but the announcement does not establish how much the models improve real-world discovery or development outcomes.
